臨床整形外科42巻2号

2007年02月発行

論述

イホスファミド脳症に対するメチレンブルーの治療的・予防的効果―骨軟部肉腫に対する化学療法での検討

著者： 田地野崇宏¹ 菊地臣一¹ 紺野慎一¹ 山田仁¹ 武田明²

所属機関： ¹福島県立医科大学整形外科 ²総合南東北病院整形外科

ページ範囲：P.107 - P.114

　骨軟部肉腫の40例に行われたイホスファミド併用化学療法120コースを対象に，イホスファミド脳症の頻度，重症度，および危険因子を調査した．また，メチレンブルーの脳症治療・予防効果についても検討した．脳症は，16例（40％），28コース（23.3％）に生じた．症状は，「傾眠」，「錯乱」，「気分変動―興奮」が多かった．重度の脳症はイホスファミドが9g/m²以上投与された時に生じた．シスプラチンの投与歴が脳症の有意な危険因子であった．メチレンブルーの治療効果は明らかではなかったが，予防効果が示された．

参考文献

1）Anderson NR, Tandon DS：Ifosfamide extrapyramidal neurotoxicity. Cancer 68：72-75, 1991

2）Alonso JL, Nieto Y, López JA, et al：Ifosfamide encephalopathy and methylene-blue：a case report. Ann Oncol 7：643-644, 1996

3）Antman KH, Elias A, Ryan L：Ifosfamide and mesna：response and toxicity at standard-and high-dose schedules. Semin Oncol 17（Suppl 4）：68-73, 1990

4）Cantwell BMJ, Harris AL：Ifosfamide/mesa and encephalopathy. Lancet 1：752, 1985

5）Cohen MH, Creaven PJ, Tejada F, et al：PhaseⅠ clinical trial of isophosphamide（NSC-109724）. Cancer Chemother Rep 59：751-755, 1975

6）Curtin JP, Koonings PP, Gutierrez M, et al：Ifosfamide-induced neurotoxicity. Gynecol Oncol 42：193-196, 1991

7）Goren MP, Wright RK, Pratt CB, et al：Dechloroethylation of ifosfamide and neurotoxicity. Lancet 2：1219-1220, 1986

8）Goren MP, Wright RK, Pratt CB, et al：Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichrloroplatinum（Ⅱ）therapy. Cancer Res 47：1457-1460, 1987

9）Heim ME, Fiene R, Schick E, et al：Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma. J Cancer Res Clin Oncol 100：113-116, 1981

10）International J Clin Oncol 9 SupplⅡ：1-82, 2004

11）Kasper B, Harter C, Meissner J, et al：Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide? Support Care Cancer 12：205-207, 2004

12）Koenigsmann MP, Knauf WU, Fietz T, et al：Ifosfamide-induced reversible encephalopathy does not preclude from further ifosfamide treatment. Tumordiagn u Ther 20：171-175, 1999

13）Küpfer A, Aeschlimann C, Wermuth B, et al：Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 343：763-764, 1994

14）Küpfer A, Aeschlimann C, Cerny T：Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 50：249-252, 1996

15）Lind MJ, Margison JM, Cerny T, et al：Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 49：753-757, 1989

16）Meanwell CA, Blake AE, Kelly KA, et al：Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 22：815-819, 1986

17）Merimsky O, Reider-Groswasser I, Wigler N, et al：Encephalopathy in ifosfamide-treated patients. Acta Neurol Scand 86：521-525, 1992

18）Patel SR, Vadhan-Raj S, Papadopolous N, et al：High-dose ifosfamide in bone and soft tissue sarcomas：results of phaseⅡ and pilot studies―dose-response and schedule dependence. J Clin Oncol 15：2378-2384, 1997

19）Pelgrims J, De Vos F, Van den Brande J, et al：Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy：report of 12 cases and a review of the literature. Br J Cancer 82：291-294, 2000

20）Pratt CB, Green AA, Horowitz ME, et al：Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 4：1253-1261, 1986

21）Rieger C, Fiegl M, Tischer J, et al：Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 15：347-350, 2004

22）The Gastrointestinal Tumor Study Group：Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Cancer 64：2010-2013, 1989

23）Turner AR, Duong CD, Good DJ：Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clin Oncol 15：435-439, 2003

24）Watkin SW, Husband DJ, Green JA, et al：Ifosfamide encephalopathy：a reappraisal. Eur J Cancer Clin Oncol 25：1303-1310, 1989

25）Zulian GB, Tullen E, Maton B：Methylene blue for ifosfamide associated encephalopathy. New Engl J Med 332：1239-1240, 1995

26）田勢長一郎：特集/中毒の治療-頻度の高い中毒18メトヘモグロビン血症に対する還元剤の作用．救急医学 17：74-75，1993